Brandon Santiago

Brandon Santiago, Ph.D., is Director of Non-Clinical DMPK Bioanalysis at GSK, where he leads bioanalytical support spanning discovery and preclinical safety programs across small molecules and emerging modalities, including LC-MS analysis of oligonucleotides, proteins, and antibody- and oligonucleotide-drug conjugates, as well as externalized GLP toxicology bioanalysis. He recently led a $2M+ automation initiative to build a fully autonomous workcell integrating in vitro assay and bioanalytical support. Since joining GSK in 2016, he has held progressively senior scientific and managerial roles within the ADME organization, and previously chaired GSK's global Mass Spectrometry Interest Group. He earned his Ph.D. in Analytical Chemistry from the University of North Carolina at Chapel Hill under Gary L. Glish, studying differential ion mobility spectrometry, and holds a B.S. in Chemistry and Mathematics from Wingate University.